FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020108440> ?p ?o ?g. }

• W2020108440 endingPage "6369" @default.
• W2020108440 startingPage "6363" @default.
• W2020108440 abstract "Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7 nM, FMS cell IC50 6.1 nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats." @default.
• W2020108440 created "2016-06-24" @default.
• W2020108440 creator A5000913274 @default.
• W2020108440 creator A5011788593 @default.
• W2020108440 creator A5018808111 @default.
• W2020108440 creator A5022552953 @default.
• W2020108440 creator A5027528883 @default.
• W2020108440 creator A5029802130 @default.
• W2020108440 creator A5038281616 @default.
• W2020108440 creator A5042762022 @default.
• W2020108440 creator A5043090781 @default.
• W2020108440 creator A5053900840 @default.
• W2020108440 creator A5065114850 @default.
• W2020108440 creator A5065203471 @default.
• W2020108440 creator A5071133995 @default.
• W2020108440 creator A5075789947 @default.
• W2020108440 creator A5078634023 @default.
• W2020108440 creator A5080735476 @default.
• W2020108440 creator A5082457024 @default.
• W2020108440 creator A5087559004 @default.
• W2020108440 date "2013-12-01" @default.
• W2020108440 modified "2023-09-26" @default.
• W2020108440 title "Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors" @default.
• W2020108440 cites W1964756939 @default.
• W2020108440 cites W1969576732 @default.
• W2020108440 cites W1984627852 @default.
• W2020108440 cites W1987493492 @default.
• W2020108440 cites W2008032601 @default.
• W2020108440 cites W2008621673 @default.
• W2020108440 cites W2011682148 @default.
• W2020108440 cites W2014203427 @default.
• W2020108440 cites W2033472212 @default.
• W2020108440 cites W2050789665 @default.
• W2020108440 cites W2053454726 @default.
• W2020108440 cites W2064395979 @default.
• W2020108440 cites W2075586758 @default.
• W2020108440 cites W2076310588 @default.
• W2020108440 cites W2086930673 @default.
• W2020108440 cites W2095001129 @default.
• W2020108440 cites W2098280147 @default.
• W2020108440 cites W2129018264 @default.
• W2020108440 cites W2132733985 @default.
• W2020108440 cites W2159630741 @default.
• W2020108440 cites W2165029623 @default.
• W2020108440 cites W2166960145 @default.
• W2020108440 cites W2173997812 @default.
• W2020108440 doi "https://doi.org/10.1016/j.bmcl.2013.09.061" @default.
• W2020108440 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24138939" @default.
• W2020108440 hasPublicationYear "2013" @default.
• W2020108440 type Work @default.
• W2020108440 sameAs 2020108440 @default.
• W2020108440 citedByCount "3" @default.
• W2020108440 countsByYear W20201084402018 @default.
• W2020108440 countsByYear W20201084402020 @default.
• W2020108440 crossrefType "journal-article" @default.
• W2020108440 hasAuthorship W2020108440A5000913274 @default.
• W2020108440 hasAuthorship W2020108440A5011788593 @default.
• W2020108440 hasAuthorship W2020108440A5018808111 @default.
• W2020108440 hasAuthorship W2020108440A5022552953 @default.
• W2020108440 hasAuthorship W2020108440A5027528883 @default.
• W2020108440 hasAuthorship W2020108440A5029802130 @default.
• W2020108440 hasAuthorship W2020108440A5038281616 @default.
• W2020108440 hasAuthorship W2020108440A5042762022 @default.
• W2020108440 hasAuthorship W2020108440A5043090781 @default.
• W2020108440 hasAuthorship W2020108440A5053900840 @default.
• W2020108440 hasAuthorship W2020108440A5065114850 @default.
• W2020108440 hasAuthorship W2020108440A5065203471 @default.
• W2020108440 hasAuthorship W2020108440A5071133995 @default.
• W2020108440 hasAuthorship W2020108440A5075789947 @default.
• W2020108440 hasAuthorship W2020108440A5078634023 @default.
• W2020108440 hasAuthorship W2020108440A5080735476 @default.
• W2020108440 hasAuthorship W2020108440A5082457024 @default.
• W2020108440 hasAuthorship W2020108440A5087559004 @default.
• W2020108440 hasConcept C118792377 @default.
• W2020108440 hasConcept C126322002 @default.
• W2020108440 hasConcept C150903083 @default.
• W2020108440 hasConcept C161790260 @default.
• W2020108440 hasConcept C184235292 @default.
• W2020108440 hasConcept C185592680 @default.
• W2020108440 hasConcept C193042331 @default.
• W2020108440 hasConcept C202751555 @default.
• W2020108440 hasConcept C207001950 @default.
• W2020108440 hasConcept C2777077863 @default.
• W2020108440 hasConcept C2777575956 @default.
• W2020108440 hasConcept C2777752497 @default.
• W2020108440 hasConcept C55493867 @default.
• W2020108440 hasConcept C71924100 @default.
• W2020108440 hasConcept C86803240 @default.
• W2020108440 hasConcept C98274493 @default.
• W2020108440 hasConceptScore W2020108440C118792377 @default.
• W2020108440 hasConceptScore W2020108440C126322002 @default.
• W2020108440 hasConceptScore W2020108440C150903083 @default.
• W2020108440 hasConceptScore W2020108440C161790260 @default.
• W2020108440 hasConceptScore W2020108440C184235292 @default.
• W2020108440 hasConceptScore W2020108440C185592680 @default.
• W2020108440 hasConceptScore W2020108440C193042331 @default.
• W2020108440 hasConceptScore W2020108440C202751555 @default.
• W2020108440 hasConceptScore W2020108440C207001950 @default.

• next